First-line management of metastatic
                                                  non-small cell lung cancer: An Indian
                                                  perspective

Ghadyalpatil, N.; Pandey, Avinash; Krishnamani, Iyer; Srinivas, C.; Rafiq, S.; Hingmire, Sachin; Maturu, Venkata Nagarjuna; Reddy, Ragotham; Kumar, Kiran; Sreekanth, K.; Gurram, Bharath Chandra; Parikh, PM

doi:10.4103/sajc.sajc_294_18

Cited by 4 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 The efficacy of chemotherapy was limited with an objective response rate (ORR) of 20%~30% and the median progression-free survival (PFS) of 4~5 months. 7 When the patients progressed after first-line therapy, docetaxel, pemetrexed, gemcitabine and immunotherapy was available as secondline treatment. 8 However, the advantages of traditional second-line single-agent chemotherapy were dismal.…”

Section: Introductionmentioning

confidence: 99%

<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>

Cheng

Chai

Zhao

et al. 2020

CMAR

View full text Add to dashboard Cite

Background The aim of this study was to investigate the efficacy and safety of anlotinib for patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard regimens in real world situations and the preliminary analysis of an efficacy predictor. Methods A total of 118 patients with advanced NSCLC who progressed after standard regimens were included in this retrospective study. Efficacy was evaluated and toxicity profile was recorded. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier survival curve and multivariate analysis was adjusted using Cox regression analysis. Results All of the 118 patients with NSCLC were available for evaluation of efficacy. Complete response (CR, 0 case), partial response (PR, 10 cases), stable disease (SD, 79 cases) and progressive disease (PD, 29 cases) were evaluated according to RECIST version 1.1. In consequence, objective response rate (ORR) was 8.47% and disease control rate (DCR) was 75.42%. The median PFS of the 118 patients with NSCLC was 4.3 months and the median OS was 10.3 months. The results of Cox regression analysis suggested that ECOG score was an independent factor for PFS. The toxicity profile indicated that hypertension and hand-foot syndrome were the most common adverse reactions. Additionally, the preliminary analysis of an efficacy predictor suggested that the PFS of patients with hypertension was superior to those without hypertension. Conclusion Anlotinib is effective and safe for patients with advanced NSCLC who progressed after standard regimens in real world situations. Hypertension may be a biomarker for efficacy prediction.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>

Cheng

Chai

Zhao

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…4 Chemotherapy efficacy is dismal, with objective response rate (ORR) 20%-30% and median progression-free survival (PFS) 4-5 months. 5 Single-agent chemotherapy with docetaxel, pemetrexed, gemcitabine, and immunotherapy are alternative second-line treatment options, with additional benefits in prolonging survival after first-line treatment. 6 However, the advantages of traditional second-line treatment are limited currently.…”

Section: Introductionmentioning

confidence: 99%

Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study

Hu¹,

Li²,

Geng³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background This study aimed to explore associations between PDL1 polymorphisms and efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer (NSCLC) in a real-world setting. Methods We retrospectively recruited 148 patients with previously treated advanced NSCLC from January 2015 to December 2019 continuously. Clinical efficacy in patients receiving apatinib treatment was evaluated. Adverse reactions were documented during treatment. Biological specimens of peripheral blood and cancer tissue biopsies were obtained for the genotyping of genetic variations in PDL1 and corresponding gene-mRNA expression, respectively. Univariate association analysis between the status of PDL1 genetic variations and survival was performed with Kaplan–Meier survival analysis. Results The objective response rate of the 148 patients was 17.6% and disease-control rate 68.9%. Prognostic data suggested that median progression-free survival (PFS) was 3.8 (95% CI 3.13–4.47) months and median overall survival (OS) 10.5 (95% CI 9.06–11.95) months. Regarding PDL1 genetic variation, only rs2297136 was of clinical significance. Prognosis analysis revealed that PFS and OS for the rs2297136 genotype were significantly different. Median PFS of patients with TC/CC and TT genotypes was 3 and 4.5 months, respectively ( P =0.006). Median OS of the two genotypes was 9 and 11.6 months, respectively ( P =0.04). Furthermore, the safety profile suggested that the most common adverse reactions were hypertension, dermal toxicity, fatigue, and oral toxicity. This study failed to find any significant association between adverse reactions and rs2297136. Interestingly, mRNA-expression analysis demonstrated that mRNA expression of PDL1 in biopsy cancer–tissue specimens was significantly different based on rs2297136-genotype status ( P <0.001). Conclusion The PDL1 polymorphism rs2297136 could be used as a potential biomarker for the prognosis of patients with NSCLC receiving apatinib monotherapy.

show abstract

Lung Cancer Management in Low and Middle-Income Countries

Jiwnani

Penumadu

Ashok

et al. 2022

Thoracic Surgery Clinics

View full text Add to dashboard Cite

First-line management of metastatic non-small cell lung cancer: An Indian perspective

Abstract: Lung cancer has been the most common cancer in the world for several decades. The non-small cell lung cancer (NSCLC) constitutes approximately about 80% of the total cases of lung cancer. Therapeutic interventions in NSCLC have shifted to the target-based approach … Show more

Cited by 4 publications

References 52 publications

<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>

<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>

Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study

Lung Cancer Management in Low and Middle-Income Countries

Contact Info

Product

Resources

About